108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
STING 激动剂的纳米递送策略：迈向高效的癌症免疫治疗
Authors Zhang M, Ji Y , Liu M, Liu Y, Tong S, Cai Y, Liu M, Qu N
Received 10 June 2025
Accepted for publication 15 October 2025
Published 22 October 2025 Volume 2025:20 Pages 12805—12829
DOI https://doi.org/10.2147/IJN.S543991
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yan Shen
Meng Zhang,1 Yating Ji,1 Mingxia Liu,1 Yang Liu,1 Shiyu Tong,1 Yuqing Cai,1 Mengjiao Liu,2 Na Qu1
1School of Pharmaceutical Science, Liaoning University, Shenyang, 110036, People’s Republic of China; 2Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, North Rhine-Westphalia, 52074, Germany
Correspondence: Na Qu, Email quna@lnu.edu.cn
Abstract: cGAS-STING (cyclic GMP-AMP synthetase-interferon gene stimulator) signaling pathway has great potential in tumor treatment, and its superior performance in tumor treatment makes it a new method for tumor treatment. However, the delivery of STING agonists alone has some limitations, such as easy degradation and low bioavailability. Moreover, STING agonists are usually injected intratumorally to avoid systemic side effects caused by strong immune responses, which is not suitable for metastatic lesions. Using nanocarriers to deliver STING agonists can overcome these limitations to some extent. This review explores the collaborative foundation between nanodelivery systems and the STING signaling pathway. It systematically summarizes the existing types of STING agonists and the types of nanoscale delivery systems and analyzes the delivery strategies of STING agonist delivery systems from multiple aspects, including the tumor microenvironment (TME), tumor cell targeting, multifunctional integrated drug delivery systems, and novel biomaterial. The review elaborates on the practical applications of these strategies as well as the challenges and problems they face. Finally, it analyzes and discusses the potential future directions of STING nanodelivery systems, aiming to provide references for research in related fields and to promote the efficient application of STING agonists in cancer therapy.
Keywords: cGAS-STING, Anti-tumor therapy, Drug delivery system, Synergistic basis, Delivery strategy
1School of Pharmaceutical Science, Liaoning University, Shenyang, 110036, People’s Republic of China; 2Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, North Rhine-Westphalia, 52074, Germany
Correspondence: Na Qu, Email quna@lnu.edu.cn
Abstract: cGAS-STING (cyclic GMP-AMP synthetase-interferon gene stimulator) signaling pathway has great potential in tumor treatment, and its superior performance in tumor treatment makes it a new method for tumor treatment. However, the delivery of STING agonists alone has some limitations, such as easy degradation and low bioavailability. Moreover, STING agonists are usually injected intratumorally to avoid systemic side effects caused by strong immune responses, which is not suitable for metastatic lesions. Using nanocarriers to deliver STING agonists can overcome these limitations to some extent. This review explores the collaborative foundation between nanodelivery systems and the STING signaling pathway. It systematically summarizes the existing types of STING agonists and the types of nanoscale delivery systems and analyzes the delivery strategies of STING agonist delivery systems from multiple aspects, including the tumor microenvironment (TME), tumor cell targeting, multifunctional integrated drug delivery systems, and novel biomaterial. The review elaborates on the practical applications of these strategies as well as the challenges and problems they face. Finally, it analyzes and discusses the potential future directions of STING nanodelivery systems, aiming to provide references for research in related fields and to promote the efficient application of STING agonists in cancer therapy.
Keywords: cGAS-STING, Anti-tumor therapy, Drug delivery system, Synergistic basis, Delivery strategy